SCHEMBL547263

SCHEMBL547263

Oc1ccc2c(c1)OCC=C2

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.49
CYP3A4 P08684 1/20 0.45
CA2 P00918 3/20 0.44
CA5A P35218 2/20 0.44
ESR1 P03372 2/20 0.38
ESR2 Q92731 2/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
TRPA1 O75762 1/20 0.35
TYR P14679 1/20 0.35
TTR P02766 1/20 0.34
CA1 P00915 2/20 0.33
CA9 Q16790 2/20 0.33
CA12 O43570 1/20 0.33
APP P05067 1/20 0.33
CYP2B6 P20813 1/20 0.33
PTPRC P08575 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29771885 1.00 STS (0.49) STSCYP3A4CA2CA5AESR1
Hydrochloric Acid SCHEMBL27538842 0.98 STS (0.47) STSCYP3A4CA2CA5AESR1
SCHEMBL16005230 0.85 STS (0.44) STSESR1ESR2CA9CA12
SCHEMBL1192912 0.84 CYP3A4 (0.45) STSCYP3A4CA2CA5AESR1
SCHEMBL29790627 0.84 CYP3A4 (0.45) STSCYP3A4CA2CA5AESR1
SCHEMBL29756778 0.81 CYP3A4 (0.42) STSCYP3A4CA2CA5AESR1
SCHEMBL14344128 0.79 CYP3A4 (0.48) CYP3A4CA2CA5AESR1ESR2
SCHEMBL276961 0.76 STS (0.53) STSCA1CA9CA12CYP2B6
SCHEMBL4150416 0.76 STS (0.49) STSCA1CA9CA12CYP2B6
SCHEMBL10426769 0.76 STS (0.53) STSCA2CA1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117393035-A Method for analyzing medicinal components of astragalus glue whitening capsules for treating leukopenia by network pharmacology mode and application thereof 贵州汉方药业有限公司 2024-01-12 CN claimed
US-9078891-B2 7-hydroxy chromones as potent antioxidants UNIGEN, INC. (US) 2015-07-14 US claimed
US-20130012458-A1 7-HYDROXY CHROMONES AS POTENT ANTIOXIDANTS UNIGEN, INC. (US) 2013-01-10 US claimed
EP-1503777-B1 7-Hydroxy chromones as potent antioxidants UNIGEN INC (US) 2012-08-22 EP claimed
US-20100168223-A1 7-Hydroxy Chromones As Potent Antioxidants UNIGEN PHARMACEUTICALS, INC. (US) 2010-07-01 US claimed
US-7678772-B2 7-hydroxy chromones as potent antioxidants UNIGEN PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
EP-1503777-A4 7-HYDROXY CHROMONES AS POTENT ANTIOXIDANTS UNIGEN PHARMACEUTICALS INC (US) 2008-02-20 EP claimed
US-20050164957-A1 7-Hydroxy chromones as potent antioxidants UNIGEN PHARMACEUTICALS, INC. (US) 2005-07-28 US claimed
US-6884783-B2 7-Hydroxy chromones as potent antioxidants UNIGEN PHARMACEUTICALS, INC. (US) 2005-04-26 US claimed
EP-1503777-A1 7-HYDROXY CHROMONES AS POTENT ANTIOXIDANTS Unigen Pharmaceuticals, Inc. (US) 2005-02-09 EP claimed
WO-2003092713-A1 7-HYDROXY CHROMONES AS POTENT ANTIOXIDANTS UNIGEN PHARMACEUTICALS, INC. (US) 2003-11-13 WO claimed
US-20030207818-A1 Identification and purification of 7-hydroxychromes that exhibit potent antioxidant activity. In one embodiment the present invention includes a method for providing an antioxidant to a host in need thereof, comprising UNIGEN, INC. 2003-11-06 US claimed
JP-10245391-A None JP disclosed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
CN-121005692-A Burisperidone efficient synthesis method of (2) 山东新时代药业有限公司 2025-11-25 CN disclosed
CN-120289476-A Synthesis method of drug intermediate 安徽大学 2025-07-11 CN disclosed
EP-0021827-B1 POLYALKYLHYDROXYCHROMENE AND PROCESS FOR PREPARING THE SAME MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1983-05-11 EP disclosed
US-4323505-A HERBICIDES, FUNGICIDES MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1982-04-06 US disclosed
EP-0021827-A1 Polyalkylhydroxychromene and process for preparing the same MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1981-01-07 EP disclosed
US-3989724-A Tetrahydropyran-2-ols HOFFMANN-LA ROCHE INC. (US) 1976-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168223-A1 7-Hydroxy Chromones As Potent Antioxidants CYP27A1, NOX4, ROS1 STS 1665/4885CYP3A4 94/4885CA2 2013/4885
US-20030207818-A1 Identification and purification of 7-hydroxychromes that exhibit potent antioxidant activity. In one embodiment the present invention includes a method for providing an antioxidant to a host in need thereof, comprising NQO1, KEAP1, NOX4 STS 1659/4885CYP3A4 139/4885CA2 1700/4885
US-20050164957-A1 7-Hydroxy chromones as potent antioxidants CYP27A1, NOX4, ROS1 STS 1665/4885CYP3A4 94/4885CA2 2013/4885
US-20130012458-A1 7-HYDROXY CHROMONES AS POTENT ANTIOXIDANTS CYP27A1, ROS1, CYP27B1 STS 2932/4885CYP3A4 276/4885CA2 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.